As the first drug to be approved by the FDA to inhibit tumor angiogenesis, bevacizumab is well known for its high affinity in blocking angiogenesis induced by VEGF, which can induce the proliferation and migration of endothelial cells and increase the permeability of the microvasculature [18]. Here, VEGFA is linked to neoplasm.